Industrial sector

Ebovir

Ebovir Biotechnologie Inc. is a Quebec-based biotech focused on the AI-driven research and development of RNA-based therapeutics, mRNA vaccines, and molecular diagnostics targeting infectious diseases and cancer. With our lead R&D platform, Ebo-Pulmo™, we are developing a novel stem-loop RNA innate immune activator designed to stimulate antiviral interferon pathways. In parallel, we are engineering lung-targeted lipid nanoparticles (LNPs) for precise RNA delivery to respiratory tissues.

Backed by a dedicated scientific team and proprietary patented technologies, Ebovir is committed to advancing RNA innovation in Quebec and beyond, through active collaboration with academic institutions, clinical centers, and industry partners.

https://ebovir.ca/
https://www.linkedin.com/company/ebovir-biotechnologie-inc/about/

Industry news

March 9, 2026

Médicament Québec Awards Two Major Grants for RNA Innovation with Financial Support from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE)

Learn more

June 17, 2025

MedicalExpo E-Magazine article highlights AReNA’s panelists at 2025 EFFERVESCENCE on RNA Therapies: From Pandemic Vaccines to Tomorrow’s Medicine.

Learn more

May 8, 2025

The creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies

Learn more

June 6, 2024

Ebovir

Industry news

Major financial support awarded by Genome Quebec L’Institut de recherche clinique de Montreal

Axelys presents Quebec’s RNA ecosystem to investors at an event in Montreal

The RNA Revolution Accelerates: Pharmaceutical and Biotechnology Giants Invest Billions in Next-Generation Therapies

Overview of Quebec’s RNA Therapy Sector

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

The Future of RNA Therapies: Amid Uncertainty, Quebec Emerges as a Hub for RNA Innovation.

CASTL Launches Pilot Edition of mRNA/mRNA-LNP Biomanufacturing Training – October 1–3, 2025 | Montreal

The IRCM’s Martin Sauvageau talks to Radio-Canada : End of American Funding for mRNA Vaccines

Citeline podcast episode looks at the state of RNA therapeutics with Novotech’s Tom Hickey

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

Interest for RNA Therapy Deals Keeps Growing Among Big Pharmaceuticals

Médicament Québec Awards Two Major Grants for RNA Innovation with Financial Support from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE)

AReNA shines at BIO 2025

Eli Lilly and Company to Acquire Verve Therapeutics for Up to $1.3 Billion

AReNA sponsors Rendez-vous Québec at the launch of the BIO International Convention

Pharmaceutiques Magazine spotlights Quebec, driving force for North America’s RNA Sector

DirectIndustry’s take on AReNA, Quebec’s Ambitious Plan to Become a Global RNA Therapeutics Leader

MedicalExpo E-Magazine article highlights AReNA’s panelists at 2025 EFFERVESCENCE on RNA Therapies: From Pandemic Vaccines to Tomorrow’s Medicine.

D2R et AReNA put RNA experts forward at the 92nd ACFAS Congress

AReNA’s expert panel and networking breakfast energize EFFERVESCENCE conference in Montreal

Panagiotis Prinos appointed as Director of Réseau DePTAQ

The AReNA breakfast series presents the CELLULE and the RNA valorisation and entrepreneurship team.

CASTL and the DePTAQ Network present their initiative during AReNA’s breakfast event at IRCM

Jean-Pierre Perreault is elected as Rector of Université de Sherbrooke

Two panelists represent AReNA at Leyton Connect’s 5-to-7

AReNA attended FISQ

AReNA attends CASTL’s Open Door Day

Epitopea closes their $31 million pre-Series A financing.

Congratulations to the Nobel Prize winners in Medicine!

Congratulations to the 23 recipients of the D2R funding programs

The creation of training programs to meet the needs of the RNA therapeutics industry

The creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies

A new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec

Quebec Launches AReNA to Become a Global Leader in RNA Therapies

A group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec

The long-overlooked molecule that will define a generation of science

Ebovir

Industry news

Major financial support awarded by Genome Quebec L’Institut de recherche clinique de Montreal

Axelys presents Quebec’s RNA ecosystem to investors at an event in Montreal

The RNA Revolution Accelerates: Pharmaceutical and Biotechnology Giants Invest Billions in Next-Generation Therapies

Overview of Quebec’s RNA Therapy Sector

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

The Future of RNA Therapies: Amid Uncertainty, Quebec Emerges as a Hub for RNA Innovation.

CASTL Launches Pilot Edition of mRNA/mRNA-LNP Biomanufacturing Training – October 1–3, 2025 | Montreal

The IRCM’s Martin Sauvageau talks to Radio-Canada : End of American Funding for mRNA Vaccines

Citeline podcast episode looks at the state of RNA therapeutics with Novotech’s Tom Hickey

Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic

Interest for RNA Therapy Deals Keeps Growing Among Big Pharmaceuticals

Médicament Québec Awards Two Major Grants for RNA Innovation with Financial Support from the Ministère de l’Économie, de l’Innovation et de l’Énergie (MEIE)

AReNA shines at BIO 2025

Eli Lilly and Company to Acquire Verve Therapeutics for Up to $1.3 Billion

AReNA sponsors Rendez-vous Québec at the launch of the BIO International Convention

Pharmaceutiques Magazine spotlights Quebec, driving force for North America’s RNA Sector

DirectIndustry’s take on AReNA, Quebec’s Ambitious Plan to Become a Global RNA Therapeutics Leader

MedicalExpo E-Magazine article highlights AReNA’s panelists at 2025 EFFERVESCENCE on RNA Therapies: From Pandemic Vaccines to Tomorrow’s Medicine.

D2R et AReNA put RNA experts forward at the 92nd ACFAS Congress

AReNA’s expert panel and networking breakfast energize EFFERVESCENCE conference in Montreal

Panagiotis Prinos appointed as Director of Réseau DePTAQ

The AReNA breakfast series presents the CELLULE and the RNA valorisation and entrepreneurship team.

CASTL and the DePTAQ Network present their initiative during AReNA’s breakfast event at IRCM

Jean-Pierre Perreault is elected as Rector of Université de Sherbrooke

Two panelists represent AReNA at Leyton Connect’s 5-to-7

AReNA attended FISQ

AReNA attends CASTL’s Open Door Day

Epitopea closes their $31 million pre-Series A financing.

Congratulations to the Nobel Prize winners in Medicine!

Congratulations to the 23 recipients of the D2R funding programs

The creation of training programs to meet the needs of the RNA therapeutics industry

The creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies

A new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec

Quebec Launches AReNA to Become a Global Leader in RNA Therapies

A group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec

The long-overlooked molecule that will define a generation of science

Stay up to date with the latest news on RNA therapies